PTC Therapeutics, Inc.
S&P 600
$66.06
-1.94%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Low debt: debt-to-equity of -1.73.
- Return on capital employed is healthy at 38%.
- Net profit margin is strong at 39.4%.
- Current assets comfortably cover current liabilities (current ratio 2.35).
!Watch-points
- Return on equity is on the lower side at -412.8%.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreGrey zone
1.81
This middle range was less conclusive in Altman’s study — neither clearly safe nor clearly distressed.
Piotroski F-ScoreModerate
5 / 6
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 6 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap$5.51B
Current Price$ 66.06
High / Low$ 90.87 / 57.74
Stock P/E8.49
Book Value$ -1.80
Dividend Yield0%
ROCE37.99%
ROE-412.82%
Debt to Equity-1.73
Current Ratio2.35
P/B Ratio-33.279594
EPS$ 7.78
Debt$286.63M
PAT Margin39.44%
Cash PAT$721.46M